Sarepta (SRPT) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$2.0B

Revenue (quarter)

$401.3M

Revenue growth (year over year)

−34.34%

Gross profit (trailing twelve months)

$1.2B

Gross margin

59.09%

Net income (trailing twelve months)

−$136.7M

Net income (quarter)

−$4.9M

Net income growth (year over year)

−102.48%

Net margin

−6.93%

Return on equity

−9.48%

EPS (trailing twelve months)

−$1.46

Book value per share

$14.46

P/E (trailing twelve months)

—

Price to book

1.15

Debt to assets

52.08%

Payout ratio

—

Dividend yield

—

Company profile

Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.

• Is Sarepta (SRPT) profitable?

  No. Sarepta reported a net loss of $136.7M over the trailing twelve months.

• How much revenue does Sarepta (SRPT) make?

  Sarepta generated $2.0B in revenue over the trailing twelve months, down 34.34% year over year.

• How do I buy stock in Sarepta (SRPT)?

  SRPT trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.